Hepatic resection of non-colorectal and non-neuroendocrine liver metastases – Survival benefit for patients with non-gastrointestinal primary cancers – A case-controlled study  by Slotta, Jan E. et al.
lable at ScienceDirect
International Journal of Surgery 12 (2014) 163e168
ORIGINAL RESEARCHContents lists avaiInternational Journal of Surgery
journal homepage: www.journal-surgery.netOriginal researchHepatic resection of non-colorectal and non-neuroendocrine liver
metastases e Survival beneﬁt for patients with non-gastrointestinal
primary cancers e A case-controlled study
Jan E. Slotta a,b,*,c, Jochen Schuld b,c, Sabrina Distler b, Sven Richter b, Martin K. Schilling b,
Otto Kollmar a,b
aDepartment of General, Visceral and Paediatric Surgery, University Medical Center Göttingen, Germany
bDepartment of General, Visceral, Vascular and Paediatric Surgery, Saarland University Medical Center, Homburg, Saar, Germanya r t i c l e i n f o
Article history:
Received 19 August 2013
Received in revised form
26 September 2013
Accepted 6 December 2013
Available online 14 December 2013
Keywords:
Liver metastases
Non-colorectal
Non-neuroendocrine
Surgery
Survival beneﬁt* Corresponding author. Department of General, Vi
University Medical Center Göttingen, Germany. Tel.: þ
39 14171.
E-mail address: jan.slotta@med.uni-goettingen.de
c These authors contributed equally to this work.
1743-9191/$ e see front matter  2013 Surgical Asso
http://dx.doi.org/10.1016/j.ijsu.2013.12.002a b s t r a c t
Purpose: Whereas resection of colorectal liver metastases is gold standard, there is an ongoing debate on
beneﬁt of resection of non-colorectal (NCRC) and non-neuroendocrine (NNEC) liver metastases.
Methods: The potential survival beneﬁt of patients undergoing resection of NCRC or NNEC liver me-
tastases was investigated. Data from a prospectively maintained database were reviewed over a 7-year
period. KaplaneMeier method was used for the evaluation of outcome following resection.
Results: 101 patients underwent 116 surgical procedures for synchronous and metachronous NCRC or
NNEC liver metastases with a morbidity of 23% and a mortality ofw1%. 11 patients underwent repeated
liver resection procedures. Overall 5-year survival after liver resection was 30% depending on primary
tumour site. Median survival was signiﬁcantly increased after resection of hepatic metastases from non-
gastrointestinal primaries compared to gastrointestinal primaries. Resection of hepatic metastases from
non-gastrointestinal primaries resulted in signiﬁcantly increased median survival compared to explo-
ration only. Patients with hepatic metastases from gastrointestinal primaries did not beneﬁt from hepatic
surgery.
Conclusion: Hepatic resection for liver metastases from NCRC or NNEC cancers is a save treatment
procedure. However, the decision to perform surgery should depend on the primary cancer. Especially
patients with liver metastases from non-gastrointestinal primaries proﬁt from hepatic surgery.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Liver resection for the treatment of distant cancer metastases is
a well established therapy optionwhich has been introduced in the
middle of the past century.1 As a result of improved knowledge of
liver anatomy and physiology2 as well as modern surgical tech-
niques and intensive care treatment strategies, hepatic surgery for
liver metastases has become a safe procedurewith lowmortality.3,4
Whereas the prognosis of untreated liver metastases from colo-
rectal cancer is very poor with a median survival of less than 12
months,5 resection of colorectal liver metastases representing thesceral and Paediatric Surgery,
49 551 398700; fax: þ49 551
(J.E. Slotta).
ciates Ltd. Published by Elsevier Ltonly curative treatment option improves the prognosis to a 5-year
survival rate of w40%6 and 10-year survival rates of up to 25%.7,8
Furthermore, aggressive surgical therapy of neuroendocrine liver
metastases has recently been demonstrated to improve clinical
symptoms and increase survival rates up to 83% after 3e5 years.9e12
In contrast, there is an ongoing debate on the indication for
resection of hepatic metastases from non-colorectal (NCRC) and
non-neuroendocrine (NNEC) primary tumours. In such patients,
metastases reach the liver via systemic circulation, and thus a
systemic tumour spread has to be assumed. Therefore, systemic
chemotherapy has been recommended for these patients in the
past. Furthermore, the group of patients with isolated liver me-
tastases from NCRC and NNEC is found to be small in number and
very heterogeneous due to a large variety of underlying primary
tumours. Consequently, there is a huge diversity of palliative
chemotherapy regimes for the treatment of liver metastases from
the different primaries, at least leading to a median survival of 24e
27 months in slow-growing cancers, such as renal cell carcinomasd. All rights reserved.
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cers,16 chemotherapy has shown to be ineffective as survival is only
prolonged by a few weeks. The issue of liver metastases surgery for
NCRC and NNEC is clinically important. In parallel to therapy of
colorectal cancer, cryosurgery or radio frequency ablation have
been discussed as minimally invasive local approaches in systemic
NCRC or NNEC tumour disease,17,18 but these therapies are not
established as standard treatment options for NCRC or NNEC liver
metastases yet. However, some recently published reports suggest
that patients with livermetastases fromNCRC and NNEC carcinoma
might beneﬁt from hepatic resection.19e22 A recently published
overview by Lehner et al. showed a 5-year survival rate of 27e39%
in patients undergoing liver resection of NCRC and NNEC metas-
tases.4 Interestingly, there are diverging results showing a clear-cut
impact of the localisation of the primary tumour on the respective
survival rates.4,20
Thus, the aim of the present study was to analyse the beneﬁt of
liver resection for NCRC andNNEC hepaticmetastases in the patient
collective of our large hepatobiliary referral centre. Furthermore,
the intent of the present study was to investigate if the surgical
approach for resectable livermetastases of NCRC and NNEC origin is
an effective strategy to prolong survival compared to palliative
treatment regimes and to emphasize the value of surgery in
multimodal therapy concepts.2. Patients and methods
2.1. Data acquisition
Data from all patients undergoing hepatic surgery were pro-
spectively entered in an i.s.h.-med database (GSD, Berlin, Germany)
running on a SAP platform (SAP, St Leon-Rot, Germany). For this
cohort study, data from patients undergoing liver resection for
NCRC and NNEC metastases in a 6-year period were retrieved from
that database and analysed retrospectively. Thus, for all patients all
data for any variable were available.2.2. Inclusion criteria for surgery
In all patients, resection of the primary cancer was categorized
to be formally curative as deﬁned by removal of all macroscopically
detectable tumour and microscopically clear resection margins.
Operations on the primary tumour were performed in combination
with or without chemotherapy and radiotherapy using neo-
adjuvant and adjuvant protocols. Histological classiﬁcation was
performed according to international standards.23 All patients un-
dergoing liver resection had a standardised general anaesthesia
including epidural analgesia, balanced volume status and prophy-
lactic perioperative antibiotics. In our retrospective study, all pa-
tients presenting at our hepatobiliary centre for resection of hepatic
metastases from NCRC or NNEC primaries were included. The de-
cision on operability was based on patients’ performance status,
declared patients’ will, and informed consent. Further, resectability
as well as choice of the operative procedure e selected to ensure
both adequate oncological resection margins and a maximal vol-
ume of functional hepatic parenchyma remnant e were based on
preoperative diagnostics, i.e. CT scan or magnetic resonance to-
mography. Findings after laparotomy and intraoperative ultrasound
were the ﬁnal criteria for resection of hepatic metastases or
exploration only in case of non-resectability. Criteria for non-
resectability were inﬁltration of all three liver veins, diffuse liver
metastases and non-resectable extrahepatic tumour manifesta-
tions, either detected in preoperative imaging or as intraoperative
ﬁnding. Synchronous or metachronous state of the metastases aswell as number, location (uni-lobular or bi-lobular) or size of the
metastases were no exclusion criteria for surgical exploration.2.3. Surgical procedures and postoperative follow-up
Partial hepatectomy was performed as anatomical resection
according to Couinaud,2 as non-anatomical or wedge resection and
as a combination of anatomical and non-anatomical resections
with or without Pringle’s manoeuvre, selective vascular clamping
or selective vascular occlusion. Major hepatectomy was deﬁned as
resection of three or more anatomical liver segments.24 Tissue
destruction within the parenchymal dissection line was usually
performed by ultrasonic dissection and the resectionmargins of the
remnant liver were coagulated by argon plasma beamer. Complete
lymph node dissection of the hepatoduodenal ligament was per-
formedwhen size and ﬁrmness of the lymph nodeswere suspicious
for malignant inﬁltration.
Data was recorded prospectively in our database including all
demographic details, disease-related data, medical data and data
from the peri-operative and postoperative course. Recurrence and
follow-up information from the patients was determined from the
medical records or was assessed retrospectively. Follow-up exam-
inations included CT-scan or magnetic resonance tomography
every 6 months after hepatic surgery for liver metastases.2.4. Statistical analyses
Data is expressed as absolute numbers, percent, or
mean  standard error of the mean (SEM) unless indicated other-
wise. The length of follow-up was calculated from the date of liver
resection at our institution with a median of 18 months. Compar-
isons of categorical and continuous variables were performed using
the c2-test, Fisher’s exact test if applicable and the Wilcoxon rank-
sum test. Differences between more than two groups were calcu-
lated by ANOVA followed by the recommended post-hoc test. To
clarify and structure our data, patients with neoadjuvant treatment
of liver metastases before liver surgery in our centre and loss of
follow-up were excluded from univariate and survival analyses.
Survival analyses were estimated according to the KaplaneMeier
method and compared with the long-rank test using the software
package SPSS 14.0 (SPSS GmbH Software, Munich, Germany). Pa-
tients who died from unknown cause of death were also counted as
an ‘event’ in the KaplaneMeier analysis as well as other patients
who died from tumour recurrence. P values of <0.05 were
considered signiﬁcant.3. Results
3.1. Patient demographics
101 patients underwent a total of 116 surgical procedures for
liver metastases from NCRC or NNEC primary cancers, including 24
explorations only. Our cohort comprised 57 female (56.4%) and 44
male (43.6%) patients with a mean age of 58.6  1.1 years at time of
liver surgery, among which 20.8% were older than 70 years
(Table 1).
Regarding the primary tumour, T stages 1e3 were found in
similar frequency, precise T staging could not be determined in 28
patients. 26.7% of the patients had synchronous hepaticmetastases,
deﬁned as liver metastases occurring within 6 months after diag-
nosis of the primary tumour. 48 patients had adjuvant chemo-
therapy for the respective primary tumour, and 10 underwent
chemotherapy even before liver surgery (Table 1).
Table 1
Patient demographics (n ¼ 101) and histological classiﬁcation of the primary non-
colorectal and non-neuroendocrine tumour. Data are given as mean  SEM or n.
Variable Mean  SEM or n
Gender [female/male] 57/44
ASA score 2.32  0.06
Body mass index [BMI, kg/m2] 25.44  0.49
BMI > 30 kg/m2 19
Age [years] 58.58  1.14
Age >70 years 21
Hepatitis (B/C) 1/0
Diabetes 13
Chronic kidney disease 9
Chronic heart disease 14
Chronic pulmonary disease 9
Hypertension 62
Previous abdominal operation 94
T stages primary tumour23
Tx 28
T1 24
T2 30
T3 28
T4 6
Synchronous liver metastases (M1) 27
Adjuvant chemotherapy for the primary tumour 48
Chemotherapy before liver resection 10
Time between surgery for primary tumour and
ﬁrst liver resection in our institution (months)
50.3  6.4
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Surgical procedures performed are listed in Table 2. Fourteen
patients underwent major hepatectomies with resection of three or
more liver segments (12.1%) and 78 patients underwent minor liver
resections, mostly performed as combined resections of more than
2 hepatic sites. In 24 cases, only abdominal exploration was per-
formed due to intraoperative ﬁnding of non-resectability of the
hepatic metastases (20.7%).
Local ablative procedures were performed in 7 patients to ach-
ieve total tumour destruction at the resection margin. All 7 patientsTable 2
Operative technique, operative parameters and morbidity and mortality of 101 pa-
tients undergoing 116 liver resection procedures for non-colorectal and non-
neuroendocrine liver metastases. Repeated procedures were performed in 11 pa-
tients ranging from 2 to 4 procedures. Data are given as mean  SEM or n.
Variable Mean  SEM or n
Exploration only 24
Repeated liver resection procedures (n ¼ 11 patients) 26 (2e4/patient)
Major liver resection
 Hemihepatectomy (right/left) 4/1
 Extended right/left resection 2/2
 Central resection 1
 >2 anatomical segments 4
Minor liver resection
 Segmentectomy 9
 Bisegmentectomy 21
 Atypical/wedge resections 47
 Cryosurgery only 1
Simultaneous liver and primary tumour resection 15
Hepatoduodenal lymph node dissection 6
Additional cryosurgery of liver metastases 5
Cryosurgery of the resection margin 1
Radiofrequency of liver metastases 1
Operative time [min] 168.9  7.4
Blood loss (ml) 518  79
Postoperative hospital stay (days) 11.1  0.7
ICU/intermediate care stay (days) 2.1  0.3
Complications CTC grade 325 10
Complications CTC grade 425 2
Complications CTC grade 525 1had a follow-up as described above and showed no difference from
patients undergoing a resection procedure only (data not shown).
3.3. Operative and perioperative data; morbidity and mortality
11 out of the 101 patients underwent 26 repeated liver resection
procedures overall. The operative and perioperative data are shown
in Table 2. Operative time was 169  7 min with resection times of
19 3min. Mean blood loss was 518 79ml, whereas therewas an
average blood loss of 302  77 ml associated with the resection
procedure. The maximum diameter of the resection margin was
7.6  0.5 cm. Volumetric analyses revealed a mean resection vol-
ume of 342  61 cm3.
Mortality of the 116 procedures was 0.9% because one patient
died after extended liver resection due to liver insufﬁciency and
subsequent multi organ failure (CTCAE grade 5,25 Table 2). Overall
rate of major and minor postoperative complications (CTCAE 2-3)
was low. Complications with CTCAE grades 3 and 4 were mainly
bleeding complications or bile leakages with subsequent surgical or
radiological intervention (Table 2). Average postoperative hospital
stay was 11.1  0.7 days, and ICU/IMC stay was 2.1  0.3 days.
3.4. Overall survival and tumour-free survival after liver resection
Table 3 shows anatomical associations of hepatic metastases to
the respective primary cancer. As shown, main primary tumours
were gynaecological, urogenital and gastrointestinal cancers. The
overall 1, 3, and 5-year survival rates (Table 4) for the entire cohort
of 101 patients were 66%, 43%, and 30% respectively, after the ﬁrst
occurrence of liver metastases. Overall recurrence-free 5-year sur-
vival rate was 25% after ﬁrst liver resection and liver-related
recurrence-free survival rate was 39%. Comparing gender differ-
ences in survival rates, there were no signiﬁcant differences
regarding survival rates after ﬁrst occurrence/resection of liver
metastases, overall tumour-free survival rate after ﬁrst hepatic
resection, and liver-related tumour-free survival rate (Table 4).
Analysis of the primary tumour site revealed that patients with
liver metastases from non-gastrointestinal primary tumours had a
signiﬁcantly longer survival than those with metastases of gastro-
intestinal primary tumours (p < 0.05; Fig. 1A, Table 4). However,
these groups did not differ concerning recurrence-free survival
(Table 4; Fig. 1B). Age at the time of resection as well as extent of
hepatic resection had no further impact on patient’s survival.
Subgroup analyses revealed that, in particular, those patients
undergoing resection of hepatic metastases from gastrointestinalTable 3
Site of the primary tumour grouped by anatomical association for 101 patients
undergoing hepatic resection non-colorectal and non-neuroendocrine liver metas-
tases with corresponding median survival after liver resection. Data are given as n.
Primary tumour site n Median survival [months]
Breast 24 38.20
Gastric 14 17.30
Pancreas 13 8.20
Urogenital 12 24.61
Melanoma 7 2.69
Uterus 6 20.98
Small intestine 6 57.16
Ovarian 5 15.84
Pulmonary 2 15.69
Oesophageal 2 12.48
Pharynx 2 6.00
Liposarcoma 1 40.20
Adrenal 1 13.05
Parotid 1 10.85
Thyroid 1 23.93
CUP 4 41.34
Table 4
Survival analyses of patients with non-colorectal and non-neuroendocrine liver
metastases undergoing liver resection related to variables of the primary tumour.
Data are expressed for survival rates (1, 3 and 5 years) after ﬁrst occurrence/resec-
tion of liver metastases (Phx), for the overall tumour free survival rate after ﬁrst Phx,
and the liver-related tumour free survival rate. *p < 0.05.
Variable n Survival after
Phx
Tumour-free
survival after
ﬁrst Phx
Tumour-free
survival after
Phx (liver)
1 y 3 y 5 y 1 y 3 y 5 y 1 y 3 y 5 y
Overall 101 66 43 30 66 36 25 74 48 39
Gender
Male 44 64 40 28 66 42 28 74 55 40
Female 57 68 44 31 66 33 24 74 44 38
Primary site
Gastrointestinal 37 59 33 20* 58 35 26 68 57 47
Non-gastrointestinal 64 70 49 35 70 38 26 68 51 41
Age
<70 80 70 46 31 64 33* 24 73 45 38
70 21 52 30 30 76 66 33 82 71 36
Temporal relationship
Synchronous 27 52 31 22 66 58* 58* 66 58 58
Metachronous 74 71 47 33 66 32 21 77 47 37
Repeated liver resections
Yes 11 100* 77* 60* 53 15* 15 59 22* 22
No 90 61 37 24 70 48 39 80 61 45
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only (Fig. 1C). In contrast, patients with hepatic metastases from
non-gastrointestinal had a signiﬁcantly prolonged survival after
resection compared to exploration only (p < 0.05; Fig. 1D). For
further risk stratiﬁcation, the impact of different non-
gastrointestinal primary cancers on the overall survival was ana-
lysed. Resection of hepatic metastases from gynaecological and
urogenital primary cancers resulted in a median survival of 27
months and 25 months, respectively, turning the disease in a
chronic course.
Analysis of the temporal relationship between primary cancer
and occurrence of hepatic metastases, i.e. synchronous vs. meta-
chronous occurrence of hepatic metastases, showed no signiﬁcant
differences for 1, 3 and 5-year overall survival (Table 4).
3.5. Repeated liver resections
In 11 out of 101 patients, a total of 26 repeated liver resections
were performed due to local recurrence, as indicated by ultrasound
or CT-scan. Analysis of overall survival showed a signiﬁcant survival
beneﬁt for patients undergoing repeated surgery (p < 0.05;
Table 4). Tumour-free survival rates and liver-related tumour-free
survival rates in patients with repeated hepatic resections were
signiﬁcantly reduced compared to patients with only one liver
resection procedure (p < 0.05, Table 4).
With regard to prevention of hepatic metastases, we analysed
the impact of chemotherapy for primary cancer on their occur-
rence. Interestingly, adjuvant chemotherapy was found to neither
reduce overall survival rates, nor overall tumour-free, nor liver-
related tumour-free survival rates signiﬁcantly.
4. Discussion
4.1. Patient outcome with liver metastases from NCRC and NNEC
primary cancer
A variety of possible explanations for improved outcome of
patients undergoing hepatic surgery for non-colorectal and non-
neuroendocrine liver metastases within the last few decades can
be considered. Besides advantages in preoperative diagnostics,improved surgical techniques and novel postoperative intensive
care therapy regimes may have led to increased survival rates after
hepatic surgery, as also found after resection of colorectal liver
metastases.5,8 However, due to the generalized extent of their
disease the prognosis of patients with hepatic metastases from
NCRC and NNEC primary cancer is very poor. Although resection of
hepatic metastases has been considered to be ineffective to prolong
survival and to be a rather palliative approach, several recent
publications demonstrated that hepatic surgery for metastases
might be a promising tool to prolong patients’ survival.20,21 Among
our 101 patients, we found survival rates in line with other recent
publications.20,26 Furthermore, the overall 5-year survival rate was
even comparable to that after resection of liver metastases from
colorectal cancer,8,27 which in turn is a widely accepted therapy
concept. Disease-free survival among our patients was comparable
to data demonstrated recently elsewhere.20,28 Thus, one can argue
that resection of hepatic metastases of NCRC and NNEC primary
cancers is a safe therapy option despite a systemic cancer disease.
Interestingly, disease-free survival and overall survival rates were
very similar in our cohort. This suggests that survival is strongly
correlated to recurrence of metastases, which do not necessarily
have to appear within the liver. This small difference between
overall and disease-free survival is possibly a reﬂection of systemic
tumour disease and different biological behaviour of the different
tumour entities. Admittedly, this is a retrospective analysis of
prospectively collected data, so our data concerning disease-free
survival does not allow for any conclusion on tumour biology.4.2. Surgery for liver metastases from NCRC and NNEC primary
cancers
In the literature, striking differences with regard to survival
rates after hepatic surgery for metastases depending on the origin
of the primary tumour and the extent of metastatic dissemination
are reported. For example, after resection of solitary hepatic me-
tastases of renal cell carcinomas a 5-year survival of 25e35% is
described,29 whereas 5-year survival after hepatic resection of
pancreatic metastases is only 8%.4 These diverging survival rates
demonstrate that a general recommendation for hepatic resection
of liver metastases is not reasonable. With this background we
analysed patients with liver metastases from gastrointestinal or
non-gastrointestinal primary cancers. In line with others, we found
a signiﬁcant survival beneﬁt for patients with liver metastases from
non-gastrointestinal primaries, even though there was no differ-
ence regarding recurrence-free survival.30,31 This difference in
survival rates depending on different origins of primaries has been
described to be more distinct by Schmelzle, as well as others,
showing a 5-year survival of 0% in patients with liver metastases
from gastrointestinal primary cancer.21,31e33 However, we herein
present for the ﬁrst time a 5-year survival rate of 20% in patients
within a median follow-up time of 18 months undergoing hepatic
surgery for metastases from NCRC or NNEC gastrointestinal pri-
maries. This surprisingly high survival rate might be due to an
aggressive surgical treatment, including central hepatic resections
or extended hepatic resections, which are surgical procedures not
performed routinely in all surgical departments. Our data adds
information on current consensus that hepatic surgery for liver
metastases from NCRC or NNEC non-gastrointestinal primary can-
cers represents a promising therapy option and has even been
proposed to be considered as a gold standard.19,33 However data for
hepatic resection of metastases from gastrointestinal primaries is
still controversial and therefore liver resection for patients with
pancreatic and upper-gastrointestinal cancers as well as melanoma
metastases should not be recommended.
time [months]
0 12 24 36 48 60 72 84 96
di
se
as
e-
fre
e 
su
rv
iva
l r
at
e
  0.0
  0.2
  0.4
  0.6
  0.8
  1.0
non-gastrointestinal primary
gastrointestinal primary
time [months]
0 12 24 36 48 60 72 84 96
su
rv
iv
a
l r
a
te
 (n
o
n
-g
as
tro
in
te
st
in
al
 p
rim
ar
y)
0,0
0,2
0,4
0,6
0,8
1,0
liver resection
exploration
time [months]
0 12 24 36 48 60 72 84 96
o
ve
ra
ll 
su
rv
iv
al
 
ra
te
  0.0
  0.2
  0.4
  0.6
  0.8
  1.0
non-gastrointestinal primary
gastrointestinal primary
BA
P=0.014
P=0.305
time [months]
0 12 24 36 48 60 72 84 96
su
rv
iv
al
 ra
te
 (g
as
tro
int
es
tin
al 
pri
ma
ry)
  0.0
  0.2
  0.4
  0.6
  0.8
  1.0
liver resection
exploration
P=0.803
C D
P<0.001
Fig. 1. KaplaneMeier curves of patient overall survival (A) and recurrence free survival (B) after hepatic resection of liver metastases of non-colorectal and non-neuroendocrine
non-gastrointestinal (solid line, n ¼ 64) and gastrointestinal primary cancers (dotted line, n ¼ 37). Panels C and D display KaplaneMeier curves of patient survival after explo-
ration only (dotted line) and after hepatic resection (solid line) of liver metastases of non-colorectal and non-neuroendocrine primary cancers for (C) gastrointestinal (n ¼ 37) and
(D) non-gastrointestinal (n ¼ 64) primary cancers.
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been demonstrated by Ercolani et al., showing worst survival rates
for resected hepatic metastases from gastrointestinal non-
colorectal and non-neuroendocrine primary cancers.19 In line
with the ﬁndings of Ercolani et al., we found a median survival of
w27 months for gynaecological and w25 months for urogenital
primary cancers, underlining the striking impact of primary
tumour site on prognosis after hepatic surgery. Although we and
others have demonstrated that surgery for hepatic metastases from
NCRC or NNEC primaries is effective to prolong patients’ survival
depending on the primary cancer,19 it is still to be discussed if
surgery is superior to local ablative procedures, as shown for he-
patic metastases of breast cancer17,18,34 or systemic chemotherapy.
This discussion is also complicated by the fact that a large variety of
chemotherapy concepts for palliative treatment of liver metastases
from NCRC or NNEC primaries were performed. Until now, most
patients with liver metastases from NCRC and NNEC primary can-
cers receive only best medical support or, wherever possible,
palliative chemotherapy. Palliative chemotherapy is considered toimprove quality of life, but not necessarily prolong survival, as
demonstrated in patients with liver metastases from gastric carci-
nomas.16 In this context, the median survival of patients receiving
palliative chemotherapy for liver metastases from pancreatic car-
cinoma or melanoma is only 4 weeks to 6 months.35,36
4.3. Repeated resections for liver metastases from NCRC and NNEC
primary cancer
Repeated liver resections are established surgical procedures for
colorectal metastases. The technique of parenchyma-sparing
resection has reduced both morbidity and mortality. In the pre-
sent study we could demonstrate that repeated liver resections are
also a successful treatment option for patients with NCRC andNNEC
liver metastases improving 3 and 5-year survival rates compared to
single hepatic surgery, which is in line with ﬁndings by Adam and
co-workers.22 Consequently, in our patients, tumour-free survival
rates and liver-related tumour-free survival rates were reduced
when undergoing repeated hepatic surgery. However, atypical
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selected cohort with small liver metastases. The small extent of
liver resection volume may explain both the low complication rate
and the good survival rates, also indicating slow tumour growth or
early detected liver metastases. Yet the small number of patients
undergoing repeated resections of hepatic metastases does not
allow a valid correlation of intrahepatic recurrence to a certain
pattern of primaries.
4.4. Limitations
The study is limited by the fact that there is no reference cohort
of patients who did not undergo surgery, but who only received
systemic chemotherapy. Unfortunately, these data were not avail-
able. This would have been helpful to elucidate the “real” survival
beneﬁt of surgical approach for treatment of hepatic metastases.
5. Conclusion
Our data underline the current concept that hepatic resection of
liver metastases from NCRC and NNEC primaries is a safe method.
Patients with hepatic metastases from non-gastrointestinal cancer
especially from gynaecological and urogenital primaries beneﬁt
from liver resection, whereas liver surgery for hepatic metastases
from upper gastrointestinal primaries, pancreatic cancer or mela-
noma could not be recommended. For those tumour entities,
therapy should be multimodal and interdisciplinary.
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